Sanofi sued Apotex (then known as GenRx) for infringement of its “clopidogrel patent”. It obtained interlocutory injunctions against Apotex against the sale of Apotex’ product and preventing Apotex from applying to list its product under the Pharmaceutical Benefits scheme (PBS). As a condition of the grant of those interlocutory injunctions, Sanofi gave the “usual undertaking as to damages”: “(a) submit to such order (if any) as the Court may consider to be just for.. Read More
IP Australia has released the Australian Intellectual Property Report 2015, with statistics on IP filings and grants and trends.
The High Court has allowed special leave to appeal from the Full Federal Court’s decision in AstraZeneca v Apotex (“Rosuvastatin”).
The Full Court has clarified what the prior use must disclose for it to be novelty destroying under the Patents Act 1990
Beach J accepted that springboard injunctions are available for patent infringement, but refused the grant on the facts.
Flick J rules that Pfizer did not breach antitrust rules by trying to maintain sales of Lipitor after it came off patent.
P Australia has issued consultation papers on removing red tape and other streamlining options
High Court grant special leave to determine patentability of Myriad’s BRCA patents.
Although it rejected the primary judge’s interpretation of s145 of the Patents Act 1990, the Full Court has nonetheless dismissed Regency’s appeal seeking to terminate its licence of MPEG patents. In 2009, Regency took a licence of a bundle of patents from the MPEG patent pool so that it could make, amongst other things, DVD and Blu-Ray players. All the patents were necessary to make MPEG–2 compliant equipment, but they related to different.. Read More
Vickery J in the Supreme Court of Victoria has had to construe how long an obligation to pay royalties under a sale of patents and technology and associated consultancy agreement lasts: ruling it is as long as the purchaser is using the “invention”.